EN 
ES 
NephCure, a leading nonprofit organization advocating to ensure that all individuals with rare, protein-spilling kidney disease have equitable access to the care and treatments that offer them the best kidney health outcome possible, is proud to celebrate C3G Awareness Day on September 25, 2026.
C3 Glomerulopathy (C3G) is an ultra-rare kidney disease caused by dysregulation of the complement system, a part of the immune system. The disease causes abnormal deposits of complement protein C3 in the kidneys, leading to inflammation and progressive kidney damage. C3G can affect both children and adults, and because symptoms can resemble those of other kidney diseases, diagnosis may be delayed.
C3G can have a significant impact on patients and families. Approximately half of people with C3G progress to kidney failure within 10 years of diagnosis, and the disease frequently recurs following kidney transplantation. These challenges underscore the importance of greater disease awareness, individualized care, continued research, and access to emerging treatments.
Recent advances in treatment are providing new hope for the C3G community. In 2025, FABHALTA® (iptacopan), was approved as the first oral treatment to reduce proteinuria in adults with C3G for adults ages 18 and older with C3G.. EMPAVELI® (pegcetacoplan) An FDA-approved treatment for adolescents and adults ages 12 and older with C3G., also approved in 2025, targets complement protein C3 and its fragment C3b to block the overactive complement pathway that can damage the kidneys.
In recognition of C3G Awareness Day, NephCure is highlighting educational resources and opportunities designed to empower patients, caregivers, and families affected by C3G.
Resources on the campaigns landing page include the free educational information such as the C3G Handbook, information about available treatments, and opportunities to connect with the C3G community. NephCure will also host a virtual C3G Patient Meet & Greet at 7:00 p.m. ET, September 25th. This livestream will provide patients and their friends and families an opportunity to connect, share experiences, ask questions, and build community.
Increased awareness can help more people recognize C3G, connect with resources, and advocate for better care and treatment.
Why Awareness Matters
C3G is an ultra-rare and serious kidney disease, but growing awareness and significant advances in research and treatment are creating new hope for the community. With two therapies now approved specifically for C3G, patients have more targeted treatment options than ever before. Yet many patients still face barriers to specialized care, accurate information, and access to the latest therapies. C3G Awareness Day brings the community together to help change that. NephCure is committed to supporting patients and families, advancing research, expanding access to information and specialized care, and working toward better treatments and, ultimately, a cure.
About NephCure
NephCure’s mission is to ensure that all individuals with rare, protein-spilling kidney disease have equitable access to the care and treatments that offer them the best kidney health outcome possible. Founded in 2000 by a group of committed patient parents, NephCure has invested more than $40 million in kidney disease research and helped create a landscape where there are now new treatments and more than 60 interventional drug trials for rare kidney diseases. NephCure is a U.S. tax-exempt 501(c)(3) public charity.
